Propanc Biopharma Inc (PPCB)

[Diggnun21]

Pfizer did not find a "cure." It found a treatment for breast cancer in a very limited population of post-menopausal women. This should in no way detract from what Propanc is doing, their target cancer(s) are of a much wider range, thier drug mechnaism of action is entirely different and their target treatable population is much larger. Rember Propanc's drugs are patented. Forget Pfizer, GO PROPANC!

FYI: Ibrance works by inhibiting molecules, known as cyclin-dependent kinases (CDKs) 4 and 6, involved in promoting the growth of cancer cells. Ibrance is intended for postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have not yet received an endocrine-based therapy. It is to be used in combination with letrozole, another FDA-approved product used to treat certain kinds of breast cancer in postmenopausal women.